Analysis of efficacy and safety of rhG-CSF used for bone marrow depression in small cell lung cancer patients after chemotherapy

VernacularTitle:重组人粒细胞集落刺激因子(rhG-CSF)对小细胞肺癌化疗后骨髓抑制的有效性和安全性分析
Author: Hao LIU ¹ ; Hao-Yang REN ; Chun-Guang SUN ; Ran LI ; Zhe-Yuan LIU ; Zhen-Man ZHAO ; Rui WANG
Author Information

1. 解放军总医院
Keywords: recombinant human granulocyte colony-stimulating factor; small cell lung cancer; chemotherapy; myelosuppression
From: The Chinese Journal of Clinical Pharmacology 2009;25(6):501-504
CountryChina
Language:Chinese
Abstract: Objective To evaluate the efficacy and safety of recombi-nant human granulocyte colony-stimulating factor ( rhG-CSF) used for chemotherapy-induced myelosuppression in small cell lung cancer (SCLC) patients. Methods Two hyndreds twenty-two cases suffering from small cell lung cancer of PLA General Hospital from 2002 to 2006 were chosen in our retrospective study, and 62 of these cases, used rhG-CSF after chemotherapy,were included in a statistics analysis. Results rhG-CSF was effective for chemotherapy-induced myelosuppression reactions and increasing significantly the number of neutropenia leukocyte and WBC (white blood cell). Average duration of recovery was 3 days and the effective rate was 95. 2%. Conclusion rhG-CSF showed high overall response rate of chemotherapy-induced myelosuppression reaction with only a few adverse reactions. But dosage and administration should be adjusted to different patients in different situations.